Skip to main content
. Author manuscript; available in PMC: 2010 Jan 15.
Published in final edited form as: Bioorg Med Chem. 2008 Dec 3;17(2):634–640. doi: 10.1016/j.bmc.2008.11.064

Figure 3.

Figure 3

Induced degradation of Hsp90 client proteins via 3g (top), 12 (middle), or 13a (bottom) inhibition of Hsp90. Compound, at varying concentrations, (μM) was evaluated for its ability to downregulate several client proteins as described in the Experimental Section. GA (500 nM) and DMSO were used as positive and negative controls, respectively.